CapsoVision
Swallowable capsule imaging and video workflows for small-bowel examinations.
Something off on this page? Send us feedback.
Profile
Sells single-use CapsoCam Plus capsules for small-bowel imaging alongside reading devices, cloud video delivery and video-reading services. Revenue is concentrated in the Capsule Endoscopy Segment, with direct U.S. sales and international distributor channels.
Builds the CapsoCam Plus system for small-bowel imaging: a swallowable, single-use capsule that captures a panoramic view, stores video internally, and avoids a body-worn recorder. CapsoCloud supplies U.S. workflow for tracking procedures, streaming video and managing exam data, while CapsoView supports local review where cloud deployment is constrained. Repeat sales of capsules are supplemented by reading devices, cloud delivery and video-reading services.
Sells directly to U.S. practices, clinics and hospitals, and reaches overseas markets primarily through exclusive distributors. Final testing, cleaning, packaging and labeling take place in Saratoga after component production and assembly in Asia. Commercial expansion depends on FDA review for the AI reading module and colon program, reimbursement and provider adoption, and single-source supply of key components.
Company facts
Key statistics
Year to date −42.0% · Average volume (30d) 91.4K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026Q2 FY26 | −$0.13 | −$0.15 | −15.4% | $3.8M | $3.6M | −4.5% | −4.86% |
| May 14, 2026Q1 FY26 | −$0.13 | −$0.15 | −15.4% | $3.0M | $2.8M | −6.2% | −11.51% |
| Mar 26, 2026Q4 FY25 | −$0.17 | −$0.16 | +5.9% | $4.2M | $3.9M | −6.0% | −0.27% |
| Nov 13, 2025Q3 FY25 | −$0.14 | −$0.17 | −21.4% | $4.3M | $3.5M | −17.7% | −9.70% |
Financial highlights
| 10 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $2.8M | $3.3M | $3.5M | $3.9M | $2.8M | $3.6M | |
| Gross profit | $1.5M | $1.8M | $1.9M | $2.0M | $1.3M | $1.9M | |
| Operating income | −$5.4M | −$4.7M | $98.0K | −$7.5M | −$7.1M | −$7.6M | |
| Net income | −$5.4M | −$4.6M | −$7.9M | −$7.4M | −$7.0M | −$7.5M | |
| Diluted EPS | −$0.12 | −$0.10 | −$0.17 | −$0.33 | −$0.15 | −$0.15 | |
| Gross margin | 53.7% | 54.6% | 54.1% | 49.9% | 47.6% | 51.4% | |
| Operating margin | -193.4% | -140.3% | 2.8% | -190.5% | -254.0% | -208.1% |
Fiscal years (4-quarter sums)FY24 $11.8M · FY25 $13.6M
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $9.1M · Total debt $687.0K · Total assets $18.6M · Shareholders' equity $13.2M
Dividends
No dividends on record.
Ownership
Shares outstanding 49.96M · Float 3.92M · 7.9% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Shen Ching Hang | 6.40M | 12.80% | 13G | Apr 15, 2026 |
| Eliyahou Harari | 5.10M | 10.20% | 13G | May 6, 2026 |
| Kioxia Corporation | 3.45M | 7.40% | 13G | Nov 12, 2025 |
| BlackRock, Inc. | 1.30M | 2.61% | 13F | May 13, 2026 |
| Vanguard Capital Management LLC | 1.03M | 2.05% | 13F | May 15, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Medtronic
Primary small-bowel capsule rival with an established colon capsule platform.
- Abbott
Cologuard is a noninvasive alternative in the future colon-screening pathway.
